article thumbnail

Precision cancer therapies: Where are we?

Drug Discovery World

Positive early signs for precision cancer therapies In the first presentation, Dr Fiona McLaughlin, CSO, provided an update on Avacta’s oncology candidates that are currently in clinical development. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Trials 52
article thumbnail

Unlocking the potential of mRNA for the future treatment of rare diseases 

Drug Discovery World

Genetic analysis tools such as Sanger sequencing by Capillary Electrophoresis (CE) and qPCR are an integral part of the vector construction process to confirm and validate that the correct sequence of the gene is inserted into the vector backbone. She is passionate about advancing research in the pursuit of healthier lives for all.